253 related articles for article (PubMed ID: 35628268)
1. A Critical Overview of Targeted Therapies for Vestibular Schwannoma.
Tamura R; Toda M
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628268
[TBL] [Abstract][Full Text] [Related]
2. [Schwannoma:Update on Molecular Profiling and Therapeutic Advances].
Tamura R; Toda M
No Shinkei Geka; 2022 Jan; 50(1):162-170. PubMed ID: 35169096
[TBL] [Abstract][Full Text] [Related]
3. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
[TBL] [Abstract][Full Text] [Related]
4. The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study.
Lewis D; Donofrio CA; O'Leary C; Li KL; Zhu X; Williams R; Djoukhadar I; Agushi E; Hannan CJ; Stapleton E; Lloyd SK; Freeman SR; Wadeson A; Rutherford SA; Hammerbeck-Ward C; Evans DG; Jackson A; Pathmanaban ON; Roncaroli F; King AT; Coope DJ
J Neurosurg; 2020 May; 134(5):1419-1429. PubMed ID: 32470937
[TBL] [Abstract][Full Text] [Related]
5. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B
J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477
[TBL] [Abstract][Full Text] [Related]
6. [Pathogenesis and molecular pathology of vestibular schwannoma].
Brodhun M; Stahn V; Harder A
HNO; 2017 May; 65(5):362-372. PubMed ID: 27421984
[TBL] [Abstract][Full Text] [Related]
7. The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients.
Taule-Sivertsen P; Bruland O; Håvik AL; Bratland E; Lund-Johansen M; Knappskog PM
J Neurooncol; 2021 Aug; 154(1):35-40. PubMed ID: 34213706
[TBL] [Abstract][Full Text] [Related]
8. Updates on Tumor Biology in Vestibular Schwannoma.
Nourbakhsh A; Dinh CT
Otolaryngol Clin North Am; 2023 Jun; 56(3):421-434. PubMed ID: 37121611
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons.
Welling DB
Otolaryngol Clin North Am; 2023 Jun; 56(3):543-556. PubMed ID: 37024334
[TBL] [Abstract][Full Text] [Related]
10. The molecular biology and novel treatments of vestibular schwannomas.
Fong B; Barkhoudarian G; Pezeshkian P; Parsa AT; Gopen Q; Yang I
J Neurosurg; 2011 Nov; 115(5):906-14. PubMed ID: 21800959
[TBL] [Abstract][Full Text] [Related]
11. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
12. Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells.
Dilwali S; Roberts D; Stankovic KM
Cancer Biol Ther; 2015; 16(1):170-5. PubMed ID: 25692621
[TBL] [Abstract][Full Text] [Related]
13. Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.
Tamura R; Morimoto Y; Sato M; Kuranari Y; Oishi Y; Kosugi K; Yoshida K; Toda M
J Neurooncol; 2020 Jan; 146(2):265-273. PubMed ID: 31897926
[TBL] [Abstract][Full Text] [Related]
14. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
Ammoun S; Flaiz C; Ristic N; Schuldt J; Hanemann CO
Cancer Res; 2008 Jul; 68(13):5236-45. PubMed ID: 18593924
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
16. [Treatment research progress on the treatment of neurofibromatosis type 2-associated vestibular schwannoma].
Zhao Y; Yang Q; Jiang Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 May; 29(10):955-8. PubMed ID: 26596021
[TBL] [Abstract][Full Text] [Related]
17. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
18. An update on the diagnosis and treatment of vestibular schwannoma.
Halliday J; Rutherford SA; McCabe MG; Evans DG
Expert Rev Neurother; 2018 Jan; 18(1):29-39. PubMed ID: 29088993
[TBL] [Abstract][Full Text] [Related]
19. Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells.
Hardin HM; Dinh CT; Huegel J; Petrilli AM; Bracho O; Allaf AM; Karajannis MA; Griswold AJ; Ivan ME; Morcos J; Gultekin SH; Telischi FF; Liu XZ; Fernandez-Valle C
Mol Cancer Ther; 2023 Nov; 22(11):1280-1289. PubMed ID: 37527526
[TBL] [Abstract][Full Text] [Related]
20. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas.
Van Gompel JJ; Agazzi S; Carlson ML; Adewumi DA; Hadjipanayis CG; Uhm JH; Olson JJ
Neurosurgery; 2018 Feb; 82(2):E52-E54. PubMed ID: 29309638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
